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Induction of labour is a common practice in obstetrics. Generally, it is 
indicated whenever continue of gestation will do more harm to both mother 
and newborn than termination of pregnancy. Many maternal medical 
problems result in a declination in placental function. Common indications 
for induction of labour include pregnancy-induced hypertension, post-date 
pregnancy, severe diabete millutus , premature rupture of membranes, 
chorioamnionitis, and whenever fetal jeopardy is suspected. 
Cervical status is considered to be the single most important factor 
for successful vaginal delivery. In case where the cervical status does not 
coincide with need for induction of labour, preparing the cervix to a 
"favourable" status is needed. 
Local administration of prostaglndinE2 is the most common method 
for pre-induction of labour. Although undoubtedly effective, it is not a 
procedure without risk. Nowadays, no method seems to be adequately 
predict the change of cervical status following local prostaglandin. Not all 
the patients with unfavourable cervix can be successfully ripen by PGE2. In 
worst situation, patients may result in uterine hyperstimulation without any 
improvement in Bishop score. The time and dose required for the cervix to 
be successfully ripen by PGE2 is vary one from another. 
The level of fetal fibronectin in cervicovaginal secretions, in addition 
to predict preterm delivery and diagnosis of rupture of membranes, studies 
has also demonstrated that it correlates to cervical ripening(Ekman et al )， 
and predict the outcome of prostaglandin induced labour(Ahner et al., 1995). 
This prospective study intend to evaluate whether the presence of 
fetal fibronectin in cervicovaginal secretions in term pregnancy pFedict the 






Fibronectin is a well characterised, mult ifunctional , cell 
interactive, adhesive glycoprotein present in a variety of extracel luar 
matrices, in plasma and in other body fluids(Ruoslahti et al.，1988). 
Fibronectin has a high molecular weight of 450,000 Daltons and was 
first found on the surface of cultured normal f ibroblasts in 1973(Hynes 
et al., 1973). 
a. Function and basic molecular structure 
Fibronectin plays a major role in various fundamental biological 
processes such as cell adhesion and migration，maintenance of normal 
cell morphology, cytoskeletal organisation, hemostasis and 
thrombosis, cell differentiat ion and oncogenic 
transformation(Schwarzbauer et al., 1991). Fibronectin is particularly 
prominent in migratory pathways for embryonic cells, such as during 
gastrulation，neural crest cell migration, and precardiac mesoderm cell 
migration. Large quantities of fibronectin are also present in clots in 
association with fibrin, where it can serve as a substrate for migratory 
cells during wound healing. 
Fibronectin is composed of two nearly identical polypeptide 
chains which are linked by a disulphide bond near their carboxyl-
terminals. Each polypeptide chain is organised into several distinct 
domains，each of which shows a specific set of interactions with other 
macromolecules. Fibronectin can interact with collagen, 
proteoglycans, fibrin, bacterial cell walls，and with receptors on many 
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eukaryotic cells. 
Despite the fact that fibronectin molecules can display a number 
of biological activities，all f ibronectin molecules appear to contain the 
same basic functional domains. Fibronectin is a blend of structurally 
different molecules (isoforms) whose make-up varies depending on the 
source. The molecule is comprised of three general types of 
homologous repeating units, termed type I，II and III. Although it is 
encoded by only one gene, fibronectin exist in a number of variant 
forms that differ in sequence at three general regions of alternative 
splicing of its precursor mRNA. 
b. Polymorphism and alternative splicing 
The polymorphism of fibronectin is caused by three sequences 
(called ED-A，ED-B, and IIICS) which may be included or excluded 
between type III modules of the fibronectin molecule depending on the 
alternative splicing patterns of a single primary transcript. (Borsi et al; 
1991). Little is known about the regulation of this alternative splicing, 
although spliced sequences tend to be retained in cellular fibronectins, 
especially by certain embryonic and malignant cells (Oyama et al., 
1989). Plasma fibronectin, generally lacks ED-A and ED-B sequences, 
and can contain 50% or less of the type IIICS spliced region 
(Hershberger and Culp., 1990). 
Fibronectin may also undergo post-translational modifications, 
where the molecule can be glycosylated, phosphorylated or sulfated 
(Mosher et al., 1989). Glycosylation of fibronectin is primarily of 
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the complex N-linked oligosaccharide type. The presence of 
carbohydrate appears to stabilise the protein against proteolysis and 
can modulate binding to collagen and slightly alter interactions with 
cells.(Zhu et al., 1985). 
c. Primary classification 
Two major isotypes of fibronectin are known; one is found in 
plasma, and the other is present in the pericellular matrix. The latter 
isotypes is secreted in the culture medium of fibroblasts(Hakomori et 
al.，1985). The plasma form of fibronectin(pFN) which is found in 
blood dissolved in plasma has a lower molecular weight and a shorter 
peptide sequence at the C-terminal region than cellular flbronectin(c 
FN), pFN is identical to a plasma protein known since 1948 under the 
name of cold insoluble globulin (CIg) because of its tendency to co-
precipitate with cryofibrinogen( Engvall et al., 1977). 
cFNs are produced by a wide variety of cell types, which secrete 
them and often organize them into extensive extracellular matrices. 
cFNs vary in composition , but they characteristically contain 
considerably higher proportions of alternatively spliced sequences than 
pFN. 
Oncofetal fibronectin(onf-FN) is a subtype of cFN which cannot 
be extracted from normal adult tissues; but can be isolated from 
various fetal connective tissues, amniotic fluid, and placenta, as well 
as from various types of human carcinoma and sarcoma. 
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2.2 Oncofetal f ibronectin 
a. Introduction 
Onf-FN is characterised by the presence of a FDC-6-def ined 
structure at a type III connecting segment (III CS). FDC-6, is an IgGl 
monoclonal antibody, which defines a unique fibronectin domain, 
located between the "Hep-2" and the "Fib-2" domains in the COOH-
terminal region of onf-FN (Matsura et al., 1985). Onf-FN can be 
detected in fetal connective t issue, placenta, amniotic fluid, hepatoma, 
and colon carcinoma as well as cell lines from fetal t i s s u e s ， a n d 
sarcoma. Onf-FN are also characterised by a high molecular weight 
(subunit Mr, 310,000-335,000). In contrast , cFN from normal adult 
t issues and pFN are characterised by a lower molecular weight 
(subunit Mr, 285,000-295,000) and lack of reactivity with FDC-6 as 
they are devoid of the FDC-6-defmed domain. 
b. Recognition by FDC-6 monoclonal antibody 
The minimum essential s t ructure required for the FDC-6 
monoclonal antibody activity is a hexapeptide sequence Val-Thr-His-
Pro-Gly-Tyr having NeuAc alpha 2——3Gal beta 1——3GalNAc or its 
core (Gal beta 1——3GalNAc or GalNAc) linked at threonine 
(Matsuura et al.，1988). 
Solely the presence of this hexapeptide seems inadequate for the 
reactivity with the FDC-6 monoclonal antibody, a conformational 
change of the molecule may also required. It is possible that a single 
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glycosylation at a defined threonine residue of the III CS region may 
induce conformational changes in the peptide to form the specific 
oncofetal epitope recognised by FDC-6 antibody. Various synthetic 
peptides including the Val-Thr-His-Pro-Gly-Tyr sequence and a 
glycopeptide having the Val-Thr-His-Pro-Gly pentapeptide with the 
same glycosylation at threonine were all inactive(Matsura et al. ,1988). 
c. Specificity of FDC-6 antibody 
Although it has been stated that fibronectin from normal adult 
plasma and tissues lacks reactivity with FDC-6 antibody, one study 
found that l%-4% of total pFN demonstrated FDC-6-reactivity in non-
pregnant human blood (Ronald et al .，1994). This finding raises 
doubts upon the reliability of cervicovaginal fetal fibronectin testing 
because it is possible that overt or occult maternal blood in the cervix 
and vagina could predispose to false positive testing for FDC-6 
reactive fibronectin. 
Another study also demonstrated a similar conclusion(Putz et 
al.,1995). In addition to the detection of fetal fibronectin in pregnant 
women, They also found fetal fibronectin in some blood samples of 
non-pregnant women, as well as in vaginal swabs of non-pfegnant 
women with vaginal bleeding. The author explained this phenomenon 
by the existance of cross-reaction of the FDC-6 antibody with hepatic 
fibronectin. 
d. Glycosylation of fetal fibronectin molecule 
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The carbohydrates of f ibronect in in human placental contain a 
large percentage of polylactosamine structures. Intact placental 
f ibronectin contains 20,000 Da of carbohydrate，whereas plasma 
fibronectin contains only 11,000 Da. Placental f ibronectin is more 
protease-resis tant than plasma fibronectin. The additional 
carbohydrate may confer the characterist ic protease resistance found 
for each of the f ibronectins.( Zhu et al., 1984 ). 
Zhu in 1985 suggested that glycosylation can affect the 
physical and biochemical propert ies of the polypeptide chain in 
glycoproteins; finding that the binding of placental f ibronectin to 
gelatin is weakened by the presence of high molecular weight 
polylactosamine carbohydrate(Zhu et al., 1985). 
Studies have also demonstrated that the amniotic fibronectin in 
late pregnancy displayed a significantly lower binding capacity for 
both heparin and gelatin than in early pregnancy ( Kottgen et al., 
1989) Indicating that the extent of hyper glycosylation of onf，FN may 
vary at different stage of pregnancy. 
e. Fibronectin and human pregnancy 
The production of placental FN is due to a local mechanism and 
it is retained in the tissue. In early chorionic tissue fibronectin is 
distributed along the trophoblast ic basement membrane on the wall of 
the fetal blood vessels, in the connective tissue core, and in the 
cytotrophoblastic cell columns. In the term placenta, fibronectin was 
mainly found in the fetal blood vessels and less intensely in the 
stroma, but not along the trophoblastic basement membrane.(Yamada 
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e t a l .， 1 9 8 7 ) 
Before conception, fibronectin plays a specific role in human 
reproduction. Hung et al in 1989 found that fibronectin levels in 
human follicular fluid correlate well with follicular size and oocyte 
maturity, suggesting a role of fibronectin in oocyte maturation. 
In early pregnancy onf-Fn plays an important role in the 
attachment of trophoblast to the uterine wall. Fibronectin in the 
embryonic extracellular matrix is important for cell migration and 
modulations in cell adhesion during morphogenesis. These functions 
can be specifically inhibited by antibodies or peptides that interfere 
with the binding of fibronectin to its integrin receptor. It is possible 
that fibronectin may not only play a permissive role in embryonic cell 
motility, but may also have an instructive function in cell behaviour. 
(Duband et al., 1990). 
The concentration of fibronectin in amniotic fluid is not 
constant throughout the pregnancy. It has been demonstrated that 
amniotic fibronectin level decrease significantly with increasing 
duration of pregnancy (Harris et al., 1988). This phenomenon reflects 
a decrease in fibronectin production in the amnion as gestation 
advances. 
In addition to changes in concentration, fibronectin in amniotic 
fluid also displays a change in its biological activities through 
pregnancy. It has been well demonstrated that glycosylation causes 
variation in the binding properties of human fibronectin. Kottgen in 
1989 demonstrated that fibronectin molecules obtained during early 
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and late gestation displayed distinct developmental differences in both 
glycosylation and binding properties. Amniotic fluid fibronectins had a 
significantly lower binding activity for both heparin and gelatin than 
plasma fibronectins , and amniotic fibronectin from late gestation 
displayed a significantly lower binding to these two ligands than that 
detected in early gestation (Kottgen et al., 1989). 
Fibronectin concentration in maternal plasma is another main 
concern as many studies have found that a high levels are associated 
with a higher incidence of pre-eclampsia. Plasma concentrations of 
fibronectin higher in pregnant women than in non-pregnant 
controls(Brady ., 1990). The plasma fibronectin remains constant up 
to the 35 th week of pregnancy, then rises significantly from the 36 th 
week onward before dropping back to the initial value at the start of 
labour. (Cunze., 1996). 
The concentration of fibronectin in maternal plasma in 
prolonged pregnancy varies differently from that in normal pregnancy. 
Fraidakis et al in 1991 found that the maternal plasma concentration 
of fibronectin during third trimester, at the time of delivery, and on 
the third post partum day was significantly lower in postterm 
pregnancies compared to the concentrations found in normal 
pregnancies(Fraidakis et al.,1991). 
f. Regulation of fetal fibronectin synthesis 
The regulation of fetal fibronectin synthesis in the feto-
placental unit is unclear but is possibly under multifunctional control. 
The placental ECM protein expression seems to be regulated by 
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tumour necrosis factor-beta (TGF-^beta) and glucocorticoids in an 
opposing way. The rate of fibronectin synthesis and levels of FN 
messenger ribonucleic acid were increased by TGF-beta treatment 
alone, where treatment with dexamethasone alone reduced median 
levels of onf-FN.(Guller et al. ,1995). 
Inflammatory products play an important role in the regulation 
� o f fetal fibronectin synthesis. The production of onf-FN by human 
amnion cells in vitro is stimulated by inflammatory products and 
mediators including lipopolysaccharide, interleukin-1 beta, and tumour 
necrosis factor-alpha.( Jackson et al., 1996) 
g. Possible mechanism of fetal fibronectin release 
The mechanism of onf-FN release into cervical vaginal secretion 
is not clearly understood. The release of onf-FN is considered to be a 
result of degradation of extracellular matrix in the amniotic membrane 
and choriodecidual unit causing the leakage of fibronectin. 
The degradation is hypothesised as a final sequence of both 
mechanical trauma and inflammatory process (Lockwood et al” 1993). 
This hypothesis seems in accordance with the finding that fibronectin 
is important in repairing fetal membranes; fibroblasts increased 
significantly at incision sites on fetal membranes and also enhanced 
fibrin clot attachment to the membranes when fibronectin was added 
to culture medium(Ancio et al., 1992). 
The finding that the presence of cytokines or onf-FN in the 
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lower genital tract was predictive of preterm also suggests that 
localised inflammatory response may result in microscopic disruption 
on the amniotic membrane, leading to leakage of onf-FN(Steven et al., 
1994). 
As proposed by Lockwood, the synthesis of prostaglandins is 
closely related to the release of onf-FN. Introduction of 
microorganisms into the intrauterine environment may induce maternal 
host-defence mechanisms, which initiate a complex cascade of physio-
chemical events including white blood cell and decidual release of 
prostaglandins and. cytokines, which enhance the degradation of the 
choriodecidual extracellular matrix and amniotic 
membranes(Lockwoood et al., 1991). 
Inflammatory products such as platelet activating factor(PAF), 
interleukin-1, interleukin-6, and tumour necrosis factor(TNF) have all 
been suggested to be responsible for increased prostaglandins 
synthesis in the amnion(Romero et al., 1992). Increased prostaglandin 
synthesis is possibly due to an increase in phospholipid mobilisation. 
Prostaglandin-induced contractions and cervical changes further 
facilitate release of onf-FN from the extracellular matrix. Induction of 
cytokine synthesis also enhances decidual activation leading to 
cervical change, increased uterine activity and the release of onf-FN. 
2.3 The uterine cervix in human labour 
a. Introduction 
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The main components of the cervix are smooth muscle，collagen, 
and connective tissue. The characterist ics of the cervix enable it to 
perform different functions at different times during the pregnancy; to 
act as a barrier，holding the products of conception inside the uterus; 
and to open at the appropriate time，allowing evacuation of the uterine 
contents. The status of the cervix is one of the important contributing 
factors to successful vaginal delivery. Despite the importance of 
cervical status for success labour, the exact mechanism of cervical 
ripening is not clearly understood. 
Normally, the cervix undergoes the process of "ripening" near 
term controlled by hormone-mediated biochemical changes, which 
mainly result in the conversion of the rigid "sphincter" into a compliant 
and easily dilating structure. This allows uterine contractility to effect 
the transport of the fetus through the birth canal. 
b. Physiological cervical ripening 
Physiological cervical ripening is characterised by a diffuse 
loosening of the collagenous connective tissue with widely scattered 
collagen fibrils and an increased amount of extracellular ground 
substance. The change in consistency during late pregnancy 
corresponds to a significant decrease in dermatan sulphate coinciding 
with a marked increase in hyaluronic acid concentration associated 
with increased water uptake. 
An inflammatory infiltrate also occurs at term in parallel with 
the ripening process and the stroma becomes oedematous and highly 
vascularised. Fibroblast activation occurs and local prostaglandin 
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production increases. The action of catabolic enzymes (collagenases， 
glycosidases), liberated from polymorphonuclear leukocytes invading 
the extracellular matrix, is responsible for the rapid dilatation of the 
cervix at parturi t ion. These changes in collagen solubility and in the 
distribution of glycosaminoglycans in the connective tissue matrix 
appears to be causally related to cervical ripening.(Von Maillot et 
al. ,1979). 
Cervical ripening appears to be an active process, rather than a 
passive process as a consequence of increased uterine activity, as in 
animal studies cervical ripening does occur even when the cervix is 
physically isolated from the uterus. However，normal ly , endocrine 
changes during the prelabor period render the uterus gradually more 
excitable as the cervix begins to ripen. Parturit ion then proceeds as 
the result of co-ordinated uterine contractions in the presence of a 
ripe cervix. It is possible that the start of myometrial contractions 
induce cervical ripening. 
Several hormonal changes occur in the last few weeks of 
pregnancy that help prepare a woman for labour. One of the important 
changes is an increase in the estrogen-progesterone ratio (Anderson et 
al.,1975). This change triggers increased prostaglandin production, 
which is believed to play a major role in the cervical ripening 
process.(Conrad et al. ,1979). 
c. Role of prostaglandins 
Prostaglandins undoubtedly play a role in the control of cervical 
ripening in the human. The production of prostaglandins increases at 
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term(Ellwood et al., 1980).Concentration of PGE2 and PGF2a 
correlate directly with the cervical score in women at term who are 
not in labour(Calder et al. ,1980). Prostaglandins and steroid hormones 
appear to be important for the control of procollagenase production. 
In addition, prostaglandins may act as the intermediary in oestrogen-
induced procollagenase production(Rajabi et al., 1991). 
d. Fibronectin and degradation of cervical matrix 
The dissociation of fibronectin is also thought to be important 
in the biological process of cervical ripening. A decrease has been 
detected in the cell-bound fibronectin is the cervix which continues 
dramatically during parturition. Szeverenyi M et al shown that the 
fibronectin content in cervical extracellular matrix drops significantly 
during delivery, having increased during the 1st and 3rd trimesters of 
pregnancy(Szeverenyi et al., 1994). 
Rath et al in 1995 found that fibronectin is one of the important 
components of the cervical extracellular matrix, and there is a marked 
reduction in cervical fibronectin content during the time of cervical 
ripening. The authors also suggested that the increase in hyaluronate 
concentrations and degradation of fibronectin may play a trigger role 
for subsequent cervical dilatation(Rath et al.,1995) 
1.4 Evaluation of cervical status 
a. Bishop score 
17 
The most widely used and accepted method for evaluating the 
changes of cervical s tatus is Bishop scoring and it variat ions, which 
are used to predict the duration of induced labour and to identify 
patients who could safely undergo such procedures. The Bishop score 
assesses five parameters: effacement , dilatation，firmness，and posit ion 
of cervix, and level of the presenting part , 
Digital cervical examination is subjective and the relative 
associations between successful labour induction and the five 
parameters appears to vary, with the strongest correlat ion observed 
with cervical dilation, whereas the association with cervical station 
and position is less important • 
It has been suggested that Bishop scoring plays a limited role in 
prolonged pregnancy in selecting suitable candidates for induction of 
labour as the cervix tends to be unfavourable for induction.( Harris et 
al. ,1983). On the other hand, some author maintain that Bishop 
scoring remains as the best and simplest method available to determine 
the duration and safety of induced labour，as none of the modifications 
to the original score has been shown to improve predictabili ty(Fuentes 
A and Williams M.,1995). 
b. Intravaginal ultrasound evaluation of cervix 
Another method for evaluating the status of cervix is 
ultrasonography. Ultrasonography has a major role in assisting 
obstetricians evaluate the pregnant uterus, and its primary focus is on 
the fetus and its development. Transvaginal ul trasound(TVS) has 
proven to be a useful modality for identifying abnormalities that relate 
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to the lower uterine segment such as placenta previa or incompetent 
cervix. Although TVS is used increasingly in fertility practice and 
gynaecological emergencies, its obstetric applications have been 
limited. 
Parameters used in TVS evaluation of cervical status include: 
the cervical length, width, dilatation, application thickness and 
cervical angles. The cervical angles are further divided into anterior 
and posterior cervical angles. The cervical index, which includes 
information about endocervical length and funnel length, is also 
sometimes used, but it can only be measured in patients with a ‘‘V_ 
shaped" pattern. This index is calculated with the equation: Cervical 
Index =(Funnel length +1)/ Endocervical length. The gross anatomy is 
also noted. The term "funnelling" is used to describe the morphologic 
changes observed with ultrasonography in the upper part of the 
endocervical canal during the process of cervical ripening. These 
changes can fall into two broad categories, "V shaped" and "U-
shaped". 
Ultrasonographic cervical scoring has been suggested as an 
objective noninvasive method for assessment of cervical status at 
term. When compared to the Bishop score, vaginal B-ultrasonic 
scanning is more accurate as 18 out of 22 cases shown immature by 
Bishop scoring were proved to have a mature cervix by B-ultrasonic 
scan(Ye et al.,1994). 
One study demonstrated that the only parameter significantly 
associated with successful induction was cervical angle(Peterson et 
al., 1991). The author also surprisingly found that there was no 
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significant correlation between digital scoring and ultrasound 
measurement, of either cervical length or dilatation. In addition, the 
difference between ultrasound and BS was greater in the primiparae 
than the multiparae. 
Accurate interpretation of TVS depends on the experience of 
the operator. Despite the presence of anatomical landmarks, the 
intervening normal cervix cannot be clearly seen. The echo textures of 
uterine corpus and the uterine cervix are indistinguishable. The 
external cervical os is not routinely visualised because of insufficient 
acoustic contrast between the external os and the vagina, however，it 
can be readily identified if fluid is introduced into the vagina. 
Potential disadvantages of TVS include the biological effects of 
ultrasound, the risk of infection, and the release of endogenous 
prostaglandins 
c. Fibronectin as a tool for evaluation of cervical status 
In 1994, Szeverenyi et al found that the fibronectin content of 
the uterine cervix dropped significantly during delivery bringing 
attention to the importance of fibronectin in cervical ripening. 
(Szeverenyi et al.,1994). 
The correlation between cervical onf-FN and cervical status has 
been studied in recent years, and onf-FN has been shown to be a 
potential indicator of cervical status as good as the Bishop score. 
Ekman et al in 1995 demonstrated that cervical fetal fibronectin 
correlated with cervical ripening. This topic will be discussed further 
later in this chapter. 
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2.5 Pre-induction cervical ripening with PGE2 
a. Introduction 
In cases where the need to induce labour does not coincide with 
a natural ripening of the cervix, attempts to induce labour may result 
in failure to deliver vaginally. Under these circumstances, methods are 
required to increase cervical compliance before induction of labour to 
increase the likelihood of spontaneous vaginal delivery. In general, a 
Bishop score of 7 is considered to indicate inducibility, while the 
cervix with a score of 4 or less benefits from pre-induction cervical 
ripening. Both medical and mechanical methods have been used to 
prepare the cervix for induction of labour. Prostaglandin E2 has been 
reported as effective and safe for cervical ripening and for induction 
of labour, and is currently the standard method in our unit. 
In 1969, Embrey et al was first observed cervical changes after 
systemic administration of prostaglandins for labour induction. 
Although prostaglandins of both F and E series have been used, the E 
series has been favoured since it is thought to be physiologic. Also, 
PGE2 is more effective then prostaglandin F2a in reducing stiffness 
and increasing elasticity, as evaluated by the stretch modulus of human 
cervical tissue(Spatling et al., 1985). 
b. Route of delivery 
Prostaglandins have now been available to assist in the cervical 
ripening process for more than two decades, but the route of delivery 
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has changed from oral administration to intravaginal, extra-amniotic or 
intracervical application. This change in the route of delivery has 
lowered the dose required for the desired cervical changes, and 
consequently lowered the incidence of side effects. The intravenous 
route of prostaglandin administration is not recommended, even 
though this rapidly achieves high blood levels, because of the high 
incidence of systemic side effects, such as vomiting and diarrhoea. 
In addition to lower side effects, clinical investigators found an 
increasing degree of reliability and efficacy as the route of 
administration approached the cervix itself. ProstaglandinE2 in the 
form of tablet, lipid-based suppositories, embedded in pessaries and 
mixed in gel vehicles has been applied intravaginally in dosages 
ranging from 1-5 mg，with a high degree of efficacy. 
c. Indications for cervical ripening with prostaglandins 
Indications for induction of cervical ripening are generally the 
same as those for induction of labour. Current indications for cervical 
ripening include: loss of placental support for the fetus prior to term; 
early rupture of the amniotic membranes with a mature fetus; the 
presence of maternal medical disease, such as diabetes or cardiac 
problems, requiring delivery prior to term; predicted fetal macrosomia 
with planned induction of early labour; and failure of the cervix to 
ripen despite prolonged latent-phase of labour. 
d. Possible Mechanism 
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The use of prostaglandins in obstetrics has undergone a rapid 
evolution since their discovery in the early 1970s. Prostaglandins are 
produced by almost every tissue in the body and serve as important 
messengers or effectors in a wide variety of functions and are the 
primary hormones of inflammation. PGE2 has been suggested to be the 
primary hormone required for cervical ripening(Brindley et al., 1988). 
MsNellis reported that the administration of PGE2 results in an 
increase in collagenase activity. It was observed that the cervical 
matrix underwent remodelling by increasing the synthesis of 
proteoglycans, especially a large chondroitin/dermatan sulfate 
proteoglycan and biglycan by three- to sixfold during prostaglandin 
E2-induced cervical ripening (Norman et al., 1993). 
Rath in 1993 also concluded that the main biochemical events 
underlying PG-induced cervical ripening are a time-dependent 
enzymatic collagen degradation by collagenases and other proteinases 
and an increase in hyaluronic acid concentration(Rath et al” 1993). 
One attractive hypothesis is that the proven role of PGE2 in 
promoting cervical ripening may be the result of a synergistic 
interaction with interleukin-8(Colditz et al., 1990). Interleukin-8 is 
alternatively described as the neutrophil attracting or activating 
peptide (NAP-1) and may be the factor responsible for bringing about 
the influx of neutrophils into cervical tissue(Junqueira et a l . ， 1 9 8 0 ) 
Thus PGE2 may act principally by dilating and increasing the 
permeability of cervical blood vessels, thereby allowing interleukin-8 
to attract neutrophils into the stroma, degranulate, and release their 
collagenolytic enzymes. 
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In addition to their importance for cervical ripening， 
prostaglandins are also suggested to be important for the initiation of 
labour. This is supported by the finding that both PGE2 and PGF2a 
and their metabolites increase during labour in both the amniotic fluid 
and peripheral circulation(Hillier et al., 1974). Some authors have 
suggested that the synthesis of prostaglandins in fetal membranes and 
the decidua play a central role in the initiation of labour.(Carry et al., 
1986). It has also been stated that a much stronger case can be made 
for the role of prostaglandins in labour than can be made for oxytocin 
(O'Brien., 1995). 
It is known that, besides being a uterotronin, PGE2 also acts 
as an uterotrophin as it increases the effect of oxytocin. The effect is 
possibly induced by stimulating cervical ripening and sensitising the 
uterus by formation of gap junctions that transform the disparate 
myometrial cells into a functional syncytium. 
e. PGE2 effectiveness and potential risks 
Most clinical trials have demonstrated that endocervical PGE2 
for pre-induction cervical ripening can reduce induction-delivery 
intervals and the duration of oxytocin administration associated with a 
significant increase in Bishop score(Trofatter et al., 1993). 
In a meta-analysis about prostaglandins in preinduction cervical 
ripening, Marc et al concluded that the administration of 
prostaglandins can decreases the likelihood of "failed induction," 
decreases the incidence of prolonged labour and increases the chances 
of spontaneous vaginal delivery. The use of prostaglandins tend to 
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reduce the incidence of both caesarean section and instrumental 
vaginal delivery no matter what route it administrated, but there was 
no statistically significant effect on incidence of caesarean section for 
any of individual administration routes(Darroca et al., 1996). 
Concerning the effects for newborn infants, there are still insufficient 
data to allow any confident statements. The author also stated that 
none of the successful prostaglandin methods for cervical ripening are 
trivial interventions as none of them act exclusively on the cervix, and 
all of them tend to increase myometrial contracti l i ty(Marc and Keirse., 
1993) 
As prostaglandins are produced by almost every tissue in the 
body and serve as important messengers or effectors in a wide variety 
of functions, the administration of prostaglandins for the purpose of 
inducing labour or ripening an unfavourable cervix is not only 
confined to the ripening of cervix but tempered by the effects of these 
agents in other systems，including the gut and brain. Also，unlike 
oxytocin which requires the induction of receptors that do not usually 
appear until the later part of pregnancy, prostaglandins receptors are 
always present in myometrial tissue. 
The use of prostaglandins for cervical ripening, while 
undoubtedly effective, is not entirely without risk The major risk is 
inappropriate use without a true indication for induction(Keirse et al., 
1989). Both PGF2a and PGE2 have gastrointestinal side effects; in 
addition, prostaglandins may result in significant uterine contractions 
and maternal discomfort. A significantly proportion of women may 
actually go into labour following prostaglandin ripening prior to the 
formal induction process. The propensity of prostaglandins to cause 
myometrial contraction; may result in hyperstimulation, with 
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subsequent fetal heart rate abnormalities requiring emergency delivery. 
Beside the risks mentioned above, other potential side effect of 
prostaglandin include sensitivity to p ros tag land ins， fever， fa i l ed 
ripening and failed induction. Although the route of PGE2 
administration has now been changed to local application instead of 
the systemic route, cases of hyperstimulation have been repor ted. 
f. Other cervical ripening techniques and agents 
Mechanical methods have been used successfully to dilate the 
unripe cervix in conjunction with induction of labour. One of the 
commonly used device is Foley catheter balloon. Devices of this sort , 
however, that must be passed through the vagina and the external 
cervical os to be posit ioned near the amniotic membranes, can pose at 
least a theoretical risk of introducing bacteria into the area. Overall, 
data from studies does not support the insertion of mechanical devices 
into the cervix as a useful approach to cervical ripening before 
induction of labour(Keirse et al., 1989). 
A hormonal approach to cervical ripening has also been used. 
Both estrogen and estrogen precursors in gel form or directly applied 
to the cervical t issues have proven effective in increasing cervical 
ripeness and in reducing the length' of labour and the need for 
caesarean section. Estrogen may also be a acceptable method of 
inducing cervical ripening in the presence of unexplained bleeding, 
which is a contraindication for prostaglandin administration( Gordon 
et a l .，1977) . 
The androgen dehydroepiandrosterone . sulfate(DHEAS)， 
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administrated through intravenous infusion, also has been shown to 
increase Bishop scores significantly. The hormone relaxin had also 
been reported to be effective (Evans et al.，1983). 
g. Prediction for outcome of induction and pre-induction cervical 
ripening with PGE2 
There are not many studies concerning factors which contribute 
to the onset of labour after pre-induction cervical ripening with 
prostaglandins. Using oxytocin or prostaglandin, Bremme et al in 
1984 found that parity and cervical dilatation showed a strong relation 
to prognosis with respect to time to delivery from start of 
contractions. The degree of cervical dilatation is the factor in the 
Bishop index that related best to the outcome of treatment(Bremme et 
al., 1984). 
It has been suggested that addition of a pre-therapeutic 
oxytocin sensitivity test to pelvic scoring would improve prediction of 
successful induction in cases of elective induction by means of PGE2 
tablets (Egarter et al., 1987). 
As concerning the value of Bishop scoring to predict the 
outcomes of using prostaglandin for induction of labour, Lyndrup et al 
found that the position and consistency of the cervix were of no 
importance. Furthermore, despite the Bishop score being predictive of 
the time required for induction to vaginal delivery, none of the 
individual Bishop subscores were related to the time between onset of 
labour and vaginal delivery. The author also suggested that the Bishop 
score should be substituted, disregarding position and consistency of 
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the cervix，but putting more weight on cervical dilatation(Lyndrup et 
al., 1992). 
Another multicentric study consisted of 1472 women 
demonstrated that only in those with a ripe cervical score as defined 
by a Bishop-Score > 7 points, has a significant shortening of the 
induction-delivery interval observed(Mink et al., 1995). 
Watson et al in 1996 evaluated factors predicting successful 
labour induction including maternal parity, the sonographic 
measurement of cervical length and the five components of the Bishop 
score. Although a model incorporating these seven factors was able to 
predict the number of hours of latent-phase labour (F = 32.1，P < 
.001), backward stepwise multiple linear regression indicated that only 
cervical dilation independently predicted the length of latent-phase 
labour. The sonographic evaluation of cervical length and maternal 
parity did not add significant independent information(Watson et al., 
1996). 
Bishop score has limited value for predicting induction-delivery 
outcomes following prostaglandins administration. The prediction is 
even less reliable in nulliparous women. Cervical dilatation is the most 
important and may even be the only parameter in the Bishop scoring 
system that can reliably predict possible outcomes. Factors such as 
maternal age, gestational age and parity should also taken into 
consideration. Sonographic evaluation of cervical status can be 
considered in patients with very low Bishop score, especially whose 
there is no cervical dilatation. 
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Facchinetti et al performed a study to specially evaluate factors 
which predict the onset of labour in patients t reated with 
prostaglandinE2 for cervical ripening. The authors found that , using 
logistic regression, three factors positively predict the onset of labour 
in patients undergoing cervical ripening with prostaglandin: first hour 
uterine contractility, basal uterine activity and gestational age. 
Interestingly, neither parity nor cervical effacement and dilatation 
were involved with the onset of labour. Patients went into labour with 
intracervical applications of PGE2 gel were characterised by an older 
maternal age and a lower rate of nulliparity, whereas no differences 
were observed in the basal Bishop score(Facchinetti et al., 1995). 
This result clearly indicates that one cannot expect to predict 
the outcome of pre-induction cervical ripening in patients with an 
unfavourable cervical status based on the basal Bishop score. This is 
because the range of scores is only from 0-4 in this selected group of 
patients and cervical dilatation, which has been shown to effectively 
predict the outcomes of prostaglandin induced labour, is usually zero. 
Looking from another angle, the major predictors of 
'Disadvantages Following Induction of Labour' by local PGE2 are 
primiparity, high maternal age, and low pelvic scores(Lyndrup et al., 
1993). 
2.6 Application of fibronectin in obstetrics 
a. Prediction of preterm delivery 
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The most common use of fibronectin measurement in obstetrics 
is for the prediction of preterm delivery. Many studies have been 
conducted to evaluate the potential and efficacy of cervicovaginal 
fetal fibronectin as a useful tool for predicting preterm delivery, and 
most of them have confirmed its value. 
In 1991, Lockwood demonstrated that a high level of 
cervicovaginal onf-FN was a biochemical marker for preterm delivery 
and stated that the presence of cervicovaginal fetal fibronectin in the 
second and third trimesters of pregnancy identifies a subgroup of 
women who are at high risk for preterm delivery. The presence of 
onf-FN identified delivery before term with a sensitivity of 81.7 
percent and a specificity of 82.5 percent. In comparison, women with 
uncomplicated pregnancies who delivered at term rarely had 
cervicovaginal fetal-fibronectin concentrations above 0.05 micrograms 
per milliliter between 21 and 37 weeks of gestation(Lockwood et al., 
1991). As compared to cervical dilatation > 1 cm and contraction 
frequency greater than or equal to eight per hour, cervicovaginal 
onf-FN predicts delivery within 7 days with a higher accuracy. 
Lockwood has further shown that cervical and vaginal detection 
of onf-FN between 24 and 36 weeks' gestation also helps the 
prediction of preterm delivery in symptom-free patients. A vaginal 
fetal fibronectin value > 50 ng/ml predicts preterm delivery with a 
sensitivity of 68%, a specificity of 80%, and positive and negative 
predictive values of 30% and 95%, respectively. According to 
stepwise logistic regression, cervical and vaginal fetal fibronectin 
levels were independent predictors of preterm delivery with adjusted 
odds ratios of 8.9(Lockwood et al., 1993). 
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In 1994, Nageot te et al also demonstrated that cervicovaginal 
onf-FN is an effective screening test for identification of asymptomatic 
patients at risk for preterm. Weekly sampling of cervicovaginal 
secretions beginning in the middle of the second trimester and 
continuing until delivery or until 34 weeks of gestation, had a 
sensitivity of 92.3% and a negative predictive value of 97.8% for 
predicting delivery before 34 weeks (Nageotte et al.，1994): 
Hellemans et al concluded that cervical onf-FN determinations 
has limited clinical value as a routinely performed screening procedure 
in a general obstetric population at low risk for preterm birth. They 
found that despite a negative predictive value of 96%, as a predictor 
for preterm delivery, cervical onf-FN detection had a sensitivity of 
60%, a specificity of 85%, and a positive predictive value of only 
25%( Hellemans et al., 1995). 
The most important use of onf-FN in obstetrics is in identifying 
those who will eventually deliver preterm among patients with 
symptoms of preterm labour. Morrison et al suggested that negative 
onf-FN is a reassuring sign in patients with regular, persistent uterine 
contractions (> 10/hr) and intact membranes: among 14 women with a 
negative onf-FN, only four developed preterm labour and only one 
patient delivered preterm. On the other hand, a positive fetal 
fibronectin in women who have false labour indicates a significant risk 
for preterm labour(specificity and positive predictive value 100%) and 
preterm delivery(specificity and positive predictive value of 72% and 
64%, respectively)( Morrison et al., 1993). 
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Senden et al in 1996 also demonstrated that a negative onf-FN 
was highly predictive (100%) of false preterm labour in patients with 
regular uterine activity, cervical dilatation < 4 cm and intact 
membranes at 25 to 35 weeks of gestation. (Senden et al.，1996). 
b. Evaluation of cervical status 
Ekman et al in 1995 demonstrated that cervical onf-FN 
correlates with cervical ripening; a level of > 0.80 microgram/ml of 
cervical fetal fibronectin indicating a favourable cervix. The study 
compared the level of cervical fibronectin between three groups of 
patients: women with unripe cervices, women with spontaneous 
cervical ripening and those with PGE2-induced cervical ripening. The 
study demonstrated that the level of cervical onf-FN was low in 
women with unripe cervices and was ten fold higher in women with 
favourable cervices. The fibronectin level was even higher after PGE2-
induced ripening. The author suggested that an increased amount of 
cervical fetal fibronectin is registered during the cervical ripening 
process.(Ekman et al., 1995). 
A recent prospective observational study of 103 patients 
undergoing induction of labour at term, also demonstrated a good 
correlation between the modified Bishop's score and the onf-FN score( 
Blanch et al., 1996). 
c. Prediction of prolonged pregnancy 
In 1994, Lockwood et al found that the level of cervicovaginal 
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onf-FN at 39 weeks of gestation is predictive of whether the gestation 
will go beyond term. A vaginal onf-FN v a l u e � = 60 ng/ml at 39 weeks' 
gestation is predictive of delivery within 10 days. In contrast, values < 
60 «g/ml identify 95% of pregnancies progressing past 41 weeks' 
gestation. After parity and cervical dilation were controlled for, 
multiple logistic regression demonstrated that a vaginal onf-FN value 
< 60 «g/ml was a significant independent predictor of pregnancies 
delivered at 41 weeks or after. (Lockwood et al., 1994). 
d. Prediction for outcomes of induced labour 
The level of onf-FN in cervicovaginal secretions correlates with 
the time required between induction and delivery in term pregnancy. 
Ahner et al demonstrated that onf-FN in the cervicovaginal secretions 
of women who have reached their expected date of confinement is a 
useful predictor of the onset of term labour and delivery. The study 
demonstrated that a qualitative onf-FN assay before induction of 
labour would have a positive accuracy 86%, and negative accuracy 88 
% in predicting delivery within 48 hours of induction of labour( Ahner 
et al., 1995). 
Ahner et al also suggested that the assessment of the onf-FN 
content in cervicovaginal secretions are helpful for the decision-
making process preceding induction of labour and can be used as a 
selection criterion for induction of labour at term. In the 64 women 
recruited, the interval between induction of labour and delivery was 
significantly shorter (p < 0.0001) in patients who were positive for 
onf-FN than those who were negative. Fibronectin positive patients 
also required a significantly lower number of prostaglandin tablets. A 
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positive result is also indicative of the success of induced labour as 
unsuccessful induction of labour only occurred in women with 
f ibronectin-negative cervicovaginal secretions(Ahner et al., 1995). 
In 1996，Garite et al also found that fetal f ibronectin can be a 
tool for the prediction of successful induction of labour. The study 
showed that term pregnant women who had a single positive result for 
vaginal onf-FN before induction of labour would had a lower 
caesarean section rate (15% vs 27%, p = 0.05) and shorter interval to 
delivery，including first dose of prostaglandin to delivery interval 
(21.3 vs 35.8 hours, p = 0.0001) and first stage of labour (14.8 vs 
21.2 hours, p = 0.0009), as compared to those had a negative vaginal 
f ibronectin assay. These differences remain similar even in nulliparous 
women with Bishop scores less or equal to 5. By stepwise logistic 
regression analysis the predictive ability of a positive result for onf-
FN was found to be independent of the Bishop score( Garite et 
al . ,1996). 
Balnch et al in 1996 also demonstrated that a higher level of 
onf-FN in cervicovaginal secretion reflects the proximity of the onset 
of induced labour. To predict a latent phase of < 8 hours, an onf-FN 
score of 3 or 4 has a sensitivity of 73% with a specificity of 83, as 
compared to modified Bishop score of greater or equal to 4 which has 
a sensitivity of 75% and a specificity of 73%. A score was depending 
on the strength of the positive fibronectin reaction with a 
concentration range from 50 wg/ml to lOOOwg/ml.The author suggested 
that the onf-FN score is as good as the modified Bishop score as an 
index of the ease with which induction of labour may be performed. 
Furthermore, the presence of onf-FN in cervicovaginal secretions may 
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be a marker of the changes in the cervix and rfiembranes that precede 






This prospective study intends to evaluate whether the presence 
of onf-FN in cervical secretions of term pregnancy is able to predict 
the outcome of pre-induction cervical ripening with PGE2. The fetal 
fibronectin concentration was determined both qualitatively and 
quantitatively using FDC-6 monoclonal antibody. 
3.2 Study population and recruitment 
The patients recruited for this study were selected from term 
pregnant women who entered the antenatal ward of the department of 
obstetrics and gynaecology of Prince of Wales Hospital. All the 
patients had documented indication for induction of labour by a 
registered medical officer. Before recruitment, all patients gave 
informed verbal consent, after the objective of the study had been 
explained. Only those patients who agreed to join the study were 
recruited. 
a. Inclusion criteria 
After excluding conditions that may interfere the result of 
cervicovaginal onf-FN assay, patients who had reached 37 weeks of 
gestation and with documented indication for induction of labour were 
recruited for the study. 
b. Exclusive criterion 
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1. Unconfirmed gestational age 
Only those who had term pregnancy were recruited. All 
the selected patients either had certain last menstural period or had 
ultrasonic scanning performed in early pregnancy to confirm the 
gestational age. If the ultrasonic gestational age did not correspond to 
the last menstrual period, the gestational age was adjusted according 
to standard charts. 
2. Premature rupture of membranes 
Concentration of onf-FN are high in amniotic fluid at term 
and therefore the test can be used as diagnostic tool for premature 
rupture of membranes(Eriksen et al., 1992).Patients with confirmed 
membrane rupture (Amniostix) were therefore excluded from the trial. 
3. Genital tract bleeding 
The FDC-6 antibody displays detectable binding to a 
clinically significant percentage of O-glycosylated human plasma 
fibronectins that are not associated with pregnancy(Ronald and 
Feinberg.， 1994). Any conditions causing contamination of the 
cervicovaginal secretions by maternal blood such as placenta praevia 
or recent antepartum haemorrhage were excluded. Patients who had 
had vaginal bleeding in early pregnancy but with no recurrence were 
not excluded. Samples would not be collected in the presence of 
macroscopic blood during speculum examination. 
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4. Genital tract infection 
It has been demonstrated that infections of the genital 
t ract can lead to a increase in onf-FN production. Localised 
inflammatory responses may lead to microscopic disruption in the 
amniotic membranes，leading to leakage of onf-FN(Inglis et al., 1994). 
Clinical evidence of vaginal infection at the time of recruitment was 
considered reason for exclusion. 
5. Others 
Digital cervical examination may increase measurable onf-
FN in symptomatic pat ients(Burrus et al.，1996)In order to avoid false 
positive detection, no patients had digital cervical examination up to 
12 hours prior to sampling. Patients who had sexual intercourse 24 
hours before the sampling were also excluded. Any patients with fetal 
congenital malformation detected during the course of ultrasonic 
scanning, were excluded. Other exclusion criteria included signs of 
fetal distress before the active phase of labour, multiple pregnancy and 
abnormal presentation. 
3.3 Measurement of Fetal Fibronectin 
Collection of specimens was conducted by medical officers 
according to the instruction in the Adeza Biochemical Specimen 
collection Kit (ROMCheck, Adeza Biomedical, Sunnyvale, California, 
USA). Two specimens were collected from every patient; one for 
qualitative and another for quantitative immunoassay. 
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3.3.1 Fetal Fibronectin Membrane Immunoassay 
a. Principle of the test 
A fast-reacting cervical swab test was used for qualitative 
detection of onf-FN in cervical secretions. The onf-FN membrane 
immunoassay is a solid-phase immunological assay. Specimens are 
combined with an antihuman fibronectin-gold colloid conjugate and 
passed through a membrane containing the monoclonal antibody FDC-
6 which is specific to onf-FN. A positive result is determined by 
observing a visible pink spot in the membrane within 5 minutes, 
b. Reagent and materials 
Sterile swab: a sterile, Dacron swab on a plastic shaft 
Membrane device: membrane with immobilized mouse 
monoclonal anti-fetal fibronectin and human fibronectin mounted in a 
plastic test device 
Conjugate: Goat anti-human fibronectin coupled to colloidal 
gold lyophilized in a protein matrix. 
Reconstitution buffer: sodium acetate buffer with 0.02% 
sodium azide as preservative. 
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Wash solution: solution of urea. 
c. Specimen collection 
Specimens are taken from both the ectocervix and the posterior 
vaginal fornix using a sterile Dacron swab containing in the Adeza 
Specimen Collection Kit at the time of sterile speculum examination. 
The Dacron swab is first carefully inserted into the vagina and gently 
rotated around the ectocervix then moved to the posterior fornix 
sweeping swab across the fornix. The total sampling process takes 
approximately 10 seconds to insure saturation of the swab which 
contains about 150ul of secretion. 
d. Assay procedure and interpretation of results 
The obtained specimen was mixed with the conjugate solution. 
The mixture was then dispensed entirely onto the surface of the 
membrane device through a dropper tip. The result was read within 15 
minutes of testing. The test was valid if the control ring was visible. A 
positive result would be recorded if a visible pink spot appeared 
within a control ring. A result with only a control ring would be 
recorded as negative. • 
3.3.2 Fetal Fibronectin Enzyme Immunoassay 
a. Principle of the test 
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A commercially available immunoassay (Adeza Biochemical 
Corp.) is used for quantitative determination of the concentration of 
onf-FN. 
This test is a solid-phase, enzyme-linked immunoabsorbent 
assay(ELISA). Specimens are incubated in microtiter wells made of 
polystyrene plastic coated with FDC-6 monoclonal. The resulting 
antibody-antigen complex is further reacted with an enzyme labeled 
antibody directed against human fibronectin to form the antigen-
antibody sandwich. After incubation with an enzyme substrate, the 
concentration of onf-FN is determined spectrophotometrically. 
b. Materials 
Microtiter well strips: Twelve 8-well strips coated with affinity 
purified FDC-6 monoclonal antibody derived from mouse. 
Antibody conjugate: Containing 10 ml of affinity purified goat 
polyclonal antibody to human fibronectin conjugated to alkaline 
phosphatase. 
Substrate: 10 ml of phenolphthalein monophosphate substrate. 
Calibrators: Each Calibrator is 2.5 ml containing human fetal 
fibronectin in a stable protein matrix with sodium azide as 
preservative. 
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Calibrator A: 1.0 ug /ml of onf-FN 
Calibrator B: 0.5 wg/ml of onf-FN 
Calibrator C: 0.1 z/g/ml of onf-FN 
Calibrator D: 0.05 wg/ml of onf-FN 
Sample diluent ( for negative control): 25 ml of a buffered protein 
matrix. 
Wash buffer concentrate: 10ml of concentrated buffer salts with 
detergent with sodium as a preservative. 
Stopping solution: 10 ml of buffer with a chelating agent 
Others: Microtiter plate reader with a 550nm filter 37 °C water bath, 
distilled water，50 and lOOul micropipets with disposable plastic tips. 
c. Specimen collection 
Specimens were collected during a sterile speculum examination 
by trained medical officer according to the instructions in the Adeza 
Biochemical Specimen Collection Kit. After absorbing cervicovaginal 
fluid across posterior fornix and around external cervical os，the 
43 
sterile dacron swab was extracted into 750ul of assay buffer (Tris 
buffer containing bovine serum albumin and protease inhibitors) to a 
approximate dilution of cervicovaginal secretion of 1:5. The specimen 
was stored under a constant temperature of -70C for a maximum 
period of six months. 
d. Assay procedure and interpretation of results 
20ml wash buffer concentrate is diluted to 2 liters with distilled 
water . Kit components are allowed to reach room temperature(20-
25°C) prior to use. All calibrators and specimen transport tubes are 
allowed to prewarm in a 37°C water bath for approximately 10 
minutes. Sample in the specimen transport tube are filtered into a 
clean，labelled sample storage tube. 
Pipet lOOul of calibrators A, B，C, D，E(sample diluent), and of 
each patients sample into each of two wells. After incubation for 1 
hour at room temperature(20-25°C), aspirate the wells and wash three 
times with the diluted wash buffer concentrate. 
After aspirating the wells thoroughly, lOOul of antibody 
conjugate was added into each well and allowed to incubate for 30 
minutes at room temperature. Wells were then washed again as 
described and lOOul of substrate was pipetted into each well. After a 
further 30 minutes incubation, 50ul of stopping solution was added to 
each well. The absorbance was read with a microtiter plate reader with 
a 550nm filter within one hour. 
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A calibration curve was obtained by plotting the concentration 
and absorbance unit of Calibrators A to E on the X-axis and Y-axis 
respectively on a linear graph paper. 
Each sample was assayed in duplicate. The absorbance of each 
sample was computed by the average absorbance of duplicate wells. 
Calibrator E，which contains no onf-FN was used as a blank. A sample 
was negative for onf-FN if the average absorbance was less than 
Calibrator D. For sample with an average absorbance greater than 
calibrator D，the concentration of the sample was obtained by co-
ordinate matching in the calibration curve. Samples with an 
absorbance greater than Calibrator A，indicated a concentration 
greater than 1.0 wg/ml. 
3.4 Cervical status determination 
After sampling taken, patients had a cervical digital examination 
to determine the need for pre-induction cervical ripening and the 
appropriate method for induction of labour. The cervical status was 




Modified Bishop scoring system 
Cervical state Score 
0 1 2 3 
Dilatation(cm) closed 1.2 3- 5+ 
Length(cm) 3 2 1 0 
Consistency firm medium soft 
Position posterior middle anterior 
Station of h e a d “ ^ -1 0 
I 
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A cervix was considered favourable if it has a sum of the score 
equal or greater than 5. No pre-induction cervical ripening would 
normally be given prior to induction of labour in this group of 
patients. 
Patients who had a cervical score less than 5 are considered to 
have an "unfavourable" cervix. These patients would be given a 3mg 
PGE2 tablet intravaginally for cervical preparation. The cervical status 
is re-examined by the same medical officer of 4-6 hours following 
PGE2 application. The patient would have induction of labour once 






Qualitative result of cervicovaginal fetal fibronectin 
Fetal Fibronectin Number of patients — Percentage 
Positive 38 45,2 




Maternal age, gestational days and parity 
Fetal Fibronectin Mean P v a l u e 
Maternal Age Negative 29.83 0 6 4 
Positive 29.32 . 
Gestational days Negative 282.48 <0.05 
Positive 290.03 ； 




Placental weight，intrapartum blood loss and birth weight 
Fetal Fibronectin Mean P value 
Placental weight(gram) Positive 567.29 0.154 
Negative 533.11 
Postpartum blood loss(ml) Positive 286.84 0.65 
Negative 266.3 ； 




Initial Bishop Score 
Fetal fibronectin Initial Bishop Score Total 
— <5 >=5 
Positive 20 18 38 
Negative 39 1 46 
Total 1 59 I 25 ^ 4 
*The sensitivity was 72 percent, the specificity was 66.1 percent, the positive 
predictive value was 47.4 percent, and the negative predictive value was 84.8 
percent 
** Pearson Chi-Square test 0.001 
***Kappa 0.336 
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The study was carried out between April 1996 and February 
1997 in the antenatal unit of department of Obstetrics and 
Gynaecology, Prince of Wales Hospital. 
Table 2 demonstrates the qualitative result of fetal f ibronectin. 
Among the 84 valid cases recruited. 38 were fibronectin positive 
(45.2%) and 46 were fibronectin negative (54.8%). 
Table 3 shows that fibronectin positive patients had a 
gestational age significantly greater than those with negative 
fibronectin. (290.03 days vs 282.48 days). No difference was observed 
in maternal age or parity between the two groups of patients. 
Table 4 displays the difference in placental weight, fetal weight 
and intrapartum vaginal blood loss between fibronectin positive and 
fibronectin negative patients. No significant difference was observed 
in these variables between the two groups. 
Table 5 demonstrates that a negative result of fibronectin had a 
moderate level of agreement with an unfavourable cervical status, and 
84.8% of fibronectin negative patients had a Bishop score less than 5. 
Totally 59 cases had an initial Bishop score less than 5. 39 
patients (66.1%) were fibronectin negative and 20 were fibronectin 
positive. For the 25 patients who had an initial Bishop score equal or 
greater than 5，18 patients (72%) were fibronectin positive and 7 were 
fibronectin negative. A positive fibronectin assay does not confidently 
predict the cervical status, as 52.6% of fibronectin positive patients 
had a Bishop score less than 5. 
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Table 11 
Need for PGE2 
Need for PGE2 Total 
Fetal fibronectin Yes No 
Positive""" 22 16 38 
Negative 41 5 46 
Total I 63 1 21 | 84 
*The sensitivity was 76.2 percent, the specificity was 65.1 percent, the positive 
predictive value was 42.1 percent, and the negative predictive value was 89,1 
percent 
**Pearson Chi-Square test 0.001 
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Table 6 i l lustrates that onf-FN negative patients are more likely 
to require pre-induction cervical ripening with PGE2 tablet . For the 46 
patients who were negative for cervicovaginal onf-FN, 41 of them 
(89.1 %) required PGE2 before induction of labour. Only 22 onf-FN 





Fetal fibronectin Number of Mean Significanc 
patients e 
Bishop Score Positive 38 2^91 0.03 
Negative 46 4.32 
Cervical dilatation Positive 38 0.4 0.007 
Negative 46 071 
Cervical length Positive 38 0 8 0.013 
Negative 46 L18 
Cervical consistency Positive 38 0.98 0.05 
Negative 46 1.34 
Cervical position Positive 38 0.4 0.68 
Negative 46 0.47 
Fetal head station Positive 38 0.33 0.108 
Negative 46 0.5 
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Table 7 compares the difference in initial Bishop score and all 
its subscores between the two groups of patients. Onf-FN posit ive 
patients had a significantly higher score in Bishop score, cervical 
dilatation, cervical length and cervical consistency as compared to the 
onf-FN patients. There was no significant difference in initial cervical 
position or fetal head station between the two groups. 
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Table 11 
Cervical scores before PGE2 
Fetal fibronectin Number of Mean Significance 
patients 
Bishop Score Positive 22 Z91 0.44 — 
Negative 41 2.61 
Cervical dilatation Positive 22 0.5 0.23 
Negative 41 0.34 
Cervical length Positive 21 077 00.63 
Negative 41 0/7 
Cervical consistency Positive 22 1.04 0.43 
Negative 41 0.93 
Cervical position Positive 22 0.27 0.46 
Negative 41 037 
Fetal head station Positive 22 0.23 0.73 
Negative 41 0.27 
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Table 11 
Cervical scores after first dose of PGE2 
Fetal fibronectin Number of Mean Significance 
patients 
Bishop Score Positive 21 5.29 0.008 
Negative 41 ^ 9 
Cervical dilatation Positive 21 1.09 0.008 
Negative 41 0 7 
Cervical length Positive 21 1.4 0.035 
Negative 41 L0 
Cervical consistency Positive 21 1.27 0.77 
Negative 41 L21 
Cervical position Positive 21 0.59 0.73 
Negative 41 0.53 
Fetal head Positive 21 077 0.026 
Negative 41 0.46 
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Concerning the 63 patients who required PGE2 for cervical 
ripening, Table 8 shows that there was no significant di f ference in 
Bishop score and all its subscores between onf-FN positive and onf-
FN negative patients before PGE2 was administrated. 
After the first dose of PGE2; Table 9 shows that onf-FN posi t ive 
patients had a significantly higher score in Bishop score, cervical 
dilatation, length, and station of fetal head than those with a negative 
onf-FN. There was no significant difference in cervical consistency or 
cervical position between the two groups. 
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Table 11 
Improvement of cervical status after first dose of PGE2 
Fetal fibronectin Mean Significance 
Bishop Score Positive 2.8 0.04 
Negative L4 
Cervical dilatation Positive 0.67 0.035 
Negative 0.37 ； 
Cervical length Positive 0.71 0.06 
Negative 0.36 
Cervical consistency Positive 0.29 0.6 
Negative 0,36 
Cervical position Positive 0.45 0.24 
: Negative 0.26 
Fetal head Positive 0.62 0.011 
Negative 0.23 
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Concerning the improvement in cervical score after a single 
dose of PGE2，Table 10 demonstrates that onf-FN positive patients 
had a significantly greater improvement in Bishop score, cervical 




Successfully ripen after first dose of PGE2 
Fetal fibronectin Successfully ripen by Total 
single dose ofPGE2 
〜 — — — — — — … 一 Y : s N o — 
Positive 13 5 18 
Negative 10 28 38 
Total 23 1 33 56 
*The sensitivity was 56.5 percent, the specificity was 84.8 percent, the positive 
predictive value was 72.2 percent, and the negative predictive value was 73.3 
percent. 
* *Pearson Chi-Square test 0.001 
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In the 63 patients who were indicated for PGE2，56 cases had 
documented cervical reassessment. All of these patents had a initial 
Bishop score less than 5. Table 11 illustrates that 72.2% of onf-FN 
positive patients (n=13) were successfully ripened by a single dose of 
PGE2. For onf-FN negative patients, 73.3% (n二28) failed to be ripen 
by a single dose of PGE2. 
64 
Table 11 
Dose ofPGE2 Taken 
Fetal Fibronectin Dose of PGE2 taken Total 
1 1 2 1 3 I 4 
Positive 19 3 0 0 22 
一 Negative 20 13 6 “ 2 — 41 
— Total 1 39 I 16 I 6 1 2 1 63 “ 
* Pearson Chi-Square test 0.024 
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Table 12 illustrates the difference in PGE2 dosage between the 
two groups of patients. In the 22 patients who were posit ive for 
onf-FN, 86.4% (n=19) required only a single dose of PGE2. The 
remaining 3 patients (13.6%) required 2 doses of PGE2. For the 19 
onf-FN positive patients who had received only one dose of PGE2, 3 
cases had onset of labour before the second dose of PGE2 was 
applied, and 1 case were not given fur ther PGE2 because of variable 
decelerations detected by CTG. None of the onf-FN positive pat ients 
required more than 2 dose of PGE2. 
For patients who were negative for fibronectin, 48.8% (n=20) 
taken a single dose of PGE2. Among these 20 patients; 11 cases (55%) 
were successfully ripened by a single dose of PGE2 (two other onf-FN 
negative patients who had successfully cervical ripening by a single 
dose of PGE2 were given a second dose of PGE2 as a tool for 
induction of labour). 9 patients were not given further PGE2 for 
different medical reasons; 3 cases had abnormal CTG detected and 2 
of them underwent emergency CS, 4 cases had onset of labour or signs 
of labour before a second dose of PGE2 could be applied, and 2 cases 
due to other non-specified reasons(by Medical officer). 19.5% (n=8) 




Proximity to labour and delivery in PGE2 treated patients 
Fetal fibronectin Number o f ~ ~ M e a n Significance 
patients 
Dose of PGE2 P o s i t i v e 2 2 1.14 0 
Negative 41 I J 6 
PGE2-Labour(min) Positive 21 696 0.005 
Negative 39 U97 
PGE2-deUvery(min) Positive 22 919 0.009 
Negative 41 1509 
Sampling-labour(min) Positive 38 513 0 
Negative 45 H33 
Sampling-delivery(min) Positive 38 818 0 
Negative 46 1477 
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Table 13 demonstrates that onf-FN positive patients required a 
significantly lower dose of PGE2 for cervical ripening. The mean 
requirement of PGE2 dose for cervical ripening was significantly lower 
for onf-FN positive patients (1.14 mg vs 1.76 mg)‘ The mean intervals 
required for onset of labour and for delivery were also f ibronect in 
dependent，whether measured from the time of sampling or of PGE2 
administration. 
Both the PGE2 to onset of labour interval and the PGE2 to 
delivery interval were significantly longer in patient with negative 
onf-FN assay. Also, onf-FN negative patients required a significantly 
longer interval from sampling to onset of labour and sampling to 
delivery as compared to onf-FN positive patient. 
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Table 11 
PGE2-labour interval within 48hrs 
Fetal fibronectinPGE2-labour Total 
interval 
— <48hrs >=48hrs 
Positive 20 — 1 
Negative 27 I? 
Total 47 1 13 ^ _ J 
*The sensitivity was 42.6 percent, the specificity was 92.3 percent, the positive 
predictive value was 95.2 percent, and the negative predictive value was 30.8 
percent. 
** Pearson Chi-Square test 0.02 
***Likelihood ratio 0.011 
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Table 14 demonstrates that patients with positive onf-FN were 
significantly less likely to have onset of labour exceeding 48 hours 
af ter PGE2 administration. 95% of onf-FN positive patients had a 
PGE2 to onset of labour interval within 48 hrs. For onf-FN negative 
patients，12 cases (30.8%) had onset of labour 48 hours af ter PGE2 
was given. In the 13 cases who had a PGE2 to onset of labour interval 
exceeding 48 hrs, 12 cases (92.3%) were onf-FN negative and only 1 
case (7.7%) was positive. 
70 
Table 11 
Sampling-labour interval within 48hrs 
Fetal fibronectin Sampling-labour Total 
interval 
“ <48hrs >=48hrs 
Positive 37 ~ 1 
Negative 32 _ 1 3 
Total 69 21 83 
*The sensitivity was 53.6 percent, the specificity was 92.9 percent, the positive 
predictive value was 97.4 percent, and the negative predictive value was 28.9 
percent. 
** Pearson Chi-Square test 0.001 
***Likelihood ratio 0.001 
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Table 15 shows that 97.4% (n=37) of onf-FN positive patients， 
as compared to 71.1% (n=32) of onf-FN negative patients, had labour 
onset within 48 hours of the cervicovaginal specimen being taken. 
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Table 11 
PGE2-delivery interval within 48 hours(including CS) 
Fetal fibronectin PGE2-deUvery interval — Jot^. 
“ <48hrs >=48hrs 
Positive 18 “ 4 Vl 
Negative 24 1Z 
Total 4 2 . 1 2 1 ^ 
*The sensitivity was 42.9 percent, the specificity was 81 percent, the positive 
predictive value was 81.8 percent, and the negative predictive value was41.5 
percent. 
**Pearson Chi-Square test 0.062 
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Table 11 
Indication for caesarean Section in patients taken PGE2 
Indication “ ~ Fetal Fibronectin — 
for Caesarean Section Positive Negative 
Fail of Induction Of Labour 1 Z 
Suspected Fetal Distress 
Cephalicpelvic Disproportion \ 
Total 3 ] 12 
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Table 16 shows that onf-FN negative patients were more likely 
to have a PGE2 administration to delivery interval in excess of 48 
hours (41.5%, n=17), as compared to positive patients. There were 
totally 21 patients delivered in excess of 48 hours after the first dose 
of PGE2 given, and 81% of them were onf-FN negative. Presence of 
onf-FN had a positive predictive value of 81.8% to predict delivery 
within 48 hours of PGE2 administration. 
For patients who taken PGE2, there were totally 15 patients 
underwent emergency C S ” 12 cases were onf-FN negative and 3 cases 
were onf-FN positive. The indications for emergency CS is i l lustrated 
in table 17. 
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Table 11 
Sampling to delivery interval within 48hrs(including CS) 
Fetal fibronectin Sampling -delivery interval Total 
<48hrs >=48hrs 
Positive 33 5 38 
Negative 29 "“ 17 46 
Total 62 22 84 . . 
*The sensitivity was 53.2 percent, the specificity was 77.3 percent, the positive 
predictive value was 86.8 percent, and the negative predictive value was 37 percent. 
**Pearson Chi-Square test 0.014 
***Likelihood ratio 0.011 
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Table 18 demonstrates that among the 22 patients who had a 
sampling to delivery interval exceeding 48 hours，77.3% (n=17)were 
onf-FN negative and 22.7% (n=5) were onf-FN positive. Presence of 
onf-FN had a positive predictive value of 86.8% to predict delivery 
within 48 hours of the cervicovaginal specimen being taken. 
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Table 11 
Accordance between qualitative and quantitative assay 
In Accordance 
Fetal Fibronectin Yes No Total 
Positive 32 2 34 
Negative" 40 6 46 
Total 72 8 | 80 — 
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Figure 1 
Quantitative measurement of onf-FN vs Bishop score 
(Labeled by qualitative result) 
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Among the 84patients recruited，4 of them failed to have 
successful specimen collected for onf-FN quantitative assay, 3 were 
onf-FN positive and 1 was onf-FN negative on qualitative assay. 
In the 80 specimens that had concentrations measured 
quantitatively, 21 (26.3%) of them had a concentration in the 
detectable range between 0.05ug/ml and 0.99ug/ml. 42 had a detected 
concentration less than 0.05ug/ml, and 17 specimens were 
quantitatively over 0.99ug/ml. 
Table 19 demonstrates that 10% of specimens (n=8) did not 
have a quantitative result in accordance to their qualitative result. In 
the 46 specimens which had tested negative with the fetal fibronectin 
membrane assay, 6 of them (13.0%) had a concentration greater than 
0.05ug/ml. Also, there were 2 specimens (5.9%) that had a detected 
concentration less than 0.05ug/ml among the 34 specimens that had a 
positive qualitative assay. 
Figure 1 demonstrates a scattergram of quantitative 
measurement of onf-FN against initial Bishop score with cases labeled 
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The hypothesis tested in this study was that，in a subgroup of 
patients receiving PGE2 for the purpose of ripening an "unripe" cervix 
as judged by a modified Bishop score < 5, measurement of onf-FN 
would enable the clinician to distinguish between those who would 
respond and those who would not. A successful response to PGE2 was 
considered as a) a change to a favourable cervix after a single 
administration of PGE2 3 mg via the vaginal route, b) successful 
induction of labour within 48 hour, c) successful labour and delivery 
within 48 hour. 
a)Detection of onf-FN in cervicovaginal secretions had a 
positive predictive value of 72.2% for successful ripening after a 
single PGE2 application. Absence of onf-FN had a negative predictive 
value of 73.3 %. The difference was significantly at the p<0.05 level. 
b) Detection of onf-FN in cervicovaginal secretions indicated 
that PGE2 ripening followed by induction of labour would be 
successful in 20 out of 21(95.2%)patients within a period of 48 hours 
of PGE2 application. Presence of onf-FN gave a positive predictive 
value of 95.2% and absence of onf-FN gave a negative predictive 
value of 30.8 %4 When all patients were considered( i.e. those 
receiving PGE2 for ripening plus those directly induced because of a 
Bishop score of 5 or more，the positive predictive value of onf-FN 
rose to 97.4% and the negative predictive value fell to 28.9 %. These 
difference were significantly at the p<0.01 level. 
c) When PGE2 to delivery interval was assessed, the presence 
of onf-FN indicated delivery would occur in <48 hours in 81% of 
cases, whereas absence of onf-FN indicated 41.5% of patients would 
remain undelivered at 48 hours. When all the patients were considered 
the presence of onf-FN predicted 86.8% of cases would deliver within 
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48 hours whereas the absence of onf-FN predicted 37% would remain 
undelivered. These difference were significant at the p<0.05 level. 
In this study, we also demonstrated the following result. Onf-
FN positive patients had a significantly higher Bishop score, and 
subscores for cervical dilatation, cervical length and cervical 
consistency as compared to onf-FN negative patient. We also 
demonstrated a moderate agreement between modified the Bishop 
score and the presence of onf-FN with a kappa 0.336. Onf-FN positive 
patients required a significantly lower dose of PGE2. The mean 
requirement of PGE2 dose for onf-FN positive patients was 1.14mg 
compared to 1.76mg for onf-FN negative patients. 
In conclusion therefore, detection of onf-FN in 
cervicovaginal secretions by the qualitative method is able to 
distinguish those patients who will respond to a single PGE2 
application for ripening of the cervix prior to induction of labour. 
Patients who had a unripe cervix with the presence of onf-FN in 
cervicovaginal secretion were more likely to be successfully ripened 
by a single dose of PGE2 and required a lower amount of PGE2，and 
these patients will normally delivered within 48 hours of PGE2 
application. Absence of onf-FN by the qualitative method indicates 
ripening and induction will be difficult in some 30-40% of patients. 
These appears to be little value in performing qualitative onf-FN 
measurement in patients who have a favourable cervix by modified 
Bishop score as these patients will almost always respond to 
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